Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure.
In patients with renal bone disease skeletal and extra-skeletal abnormalities can be visualised using conventional bone scintigraphy. Some of these abnormalities are associated with characteristic scintigraphic appearances, which are reviewed in detail, and the possible mechanisms involved are discussed. Specific imaging with iodine 123 serum amyloid P component and iodine 131 beta 2-microglobulin is also discussed in the diagnosis of beta 2-microglobulin amyloidosis specific to patients on dialysis. In the light of available evidence, it appears that bone scintigraphy plays, so far, a limited role in the clinical evaluation of skeletal and extra-skeletal abnormalities in chronic renal failure. The potential role of bone scintigraphy in identifying patients with aluminium-related bone disease needs to be investigated further, and in this respect special attention must be given to the problem of high soft-tissue activity associated with impaired renal function. Timing haemodialysis sessions before scintigraphic imaging deserves wider recognition as it reduces high soft-tissue activity, thereby allowing bone uptake to be assessed more accurately. Specific imaging of amyloidosis resulting from beta 2-microglobulin deposition is a promising technique, but the relative value of the two proposed radiopharmaceuticals needs further clarification.
de Jonge
F A
FA
Department of Diagnostic Radiology (Division of Nuclear Medicine), University Hospital Leiden, The Netherlands.
Pauwels
E K
EK
Hamdy
N A
NA
D000686:Amyloidosis / Q000000981:diagnostic imaging* / Q000209:etiology; D002114:Calcinosis / Q000000981:diagnostic imaging* / Q000209:etiology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000000981:diagnostic imaging* / Q000209:etiology; D012968:Etidronic Acid; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D015609:Organotechnetium Compounds; D011877:Radionuclide Imaging; D006435:Renal Dialysis / Q000009:adverse effects*; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives
D015609:Organotechnetium Compounds; C019561:technetium Tc 99m etidronate; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate